3D Medication Inc. (www.3d-medicines.com) is a pharmaceutical company focusing on the field of cancer treatment that has entered the commercialization stage. Adhering to the vision of “helping cancer patients live longer and better”, combined with the future trend of chronic cancer treatment, it develops next-generation oncology drugs for cancer patients around the world. The company's product line includes 12 innovative drug candidates with clinical value and differentiated or global leadership. Of these, 8 have entered clinical development or commercialization, including the world's first new PD-L1 monomonial antibody drug, which has been conditionally approved by the China Drug Administration to be marketed in China; the introduction of the first-in-class polypeptide tumor vaccine 3D189 and the Gas6/AXL inhibitor 3D229 has been approved by the FDA for global phase III MRCT clinical research; the self-developed multi-target kinase inhibitor 3D011 has also entered clinical trials In the development phase, the other 4 products targeting FGFR123\ EP4\ COX2\ CD47 respectively have also entered the clinical stage at home and abroad. Preclinical varieties also include the internationally leading dual antibody CD3xPD-L1. The company currently has an international team of more than 250 people in the development, production and commercialization of new drugs to explore better treatments for cancer patients around the world.
相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2021
已完成
2
66.7%
尚未招募
1
33.3%
暂无批准数据
- ResearchAndMarkets.com has released a comprehensive report analyzing licensing deals in biotechnology from 2020 to 2025, providing insights into deal trends and structures. - The report covers hundreds of companies including major players like AbbVie, ACADIA Pharmaceuticals, and emerging biotech firms across various therapeutic areas and technology types. - Key features include financial terms analysis covering upfront payments, milestones, and royalties, plus access to actual contract documents for due diligence purposes. - The analysis enables benchmarking of transaction values and identification of the most active dealmakers in the biotechnology licensing landscape.
- ImmuneOncia's next-generation CD47-targeting antibody IMC-002 demonstrated a 30% partial response rate when combined with lenvatinib in advanced hepatocellular carcinoma patients, significantly higher than the typical 10% seen with current second-line therapies. - The Phase 1b trial showed a favorable safety profile with 96% of adverse events being Grade 1-2, no neutropenia or thrombocytopenia, and median progression-free survival of 8.3 months. - AI-powered digital pathology analysis revealed a 60% objective response rate in patients with high CD47 expression versus no response in low-expression patients (p=0.018), supporting CD47 as a predictive biomarker. - Two patients have remained on treatment for over one year, with two of three partial responders being resistant to first-line immunotherapy, suggesting potential for sustained benefit in treatment-resistant cases.
